Grampian Area Formulary

	Grampian Area
	Formulary

Search

News

News Title
	Grampian Joint Formulary Status for SMC advice published April 2020 to December 2020 12/01/2021
	Drug Safety Update January 2021: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia Fingolimod (Gilenya▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations Letters and drug alerts sent to healthcare professionals in December 2020 08/01/2021
	Formulary Group minute - 17 November 2020 31/12/2020
	Formulary Group decisions - December 2020 31/12/2020
	Drug Safety Update December 2020: Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis Letters and drug alerts sent to healthcare professionals in November 2020 18/12/2020
	Formulary Group minute - 20 October 2020 07/12/2020
	Formulary Group decisions - November 2020 01/12/2020
	Drug Safety Update November 2020: Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy Pirfenidone (Esbriet): risk of serious liver injury, and updated advice on liver function testing Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs Isotretinoin (Roaccutane▼): contribute to expert review Letters and drug alerts sent to healthcare professionals in October 2020 17/11/2020
	Formulary Group minute - 15 September 2020 10/11/2020
	Formulary Group decisions - October 2020 03/11/2020
	MHRA: Milestone 1 million Yellow Card report for suspected side effects in #MedSafetyWeek 02/11/2020
	Drug Safety Update October 2020: 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity Flucytosine (Ancotil): new contraindication in patients with DPD deficiency Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic Every report counts: report suspected adverse drug reactions and take part in #MedSafetyWeek (2–8 November 2020) Letters and drug alerts sent to healthcare professionals in September 2020 23/10/2020
	MHRA: Warfarin and other blood thinners – reminder on safe use during COVID-19 pandemic 14/10/2020
	MHRA: Warfarin and other anticoagulants – monitoring of patients during the COVID-19 pandemic 13/10/2020
	Formulary Group minute - 18 August 2020 07/10/2020
	Formulary Group decisions - September 2020 29/09/2020
	Primary Care Prescribing Group - COVID-19 update Vitamin D (All Ages): Advice For Prescribers 25/09/2020
	Drug Safety Update September 2020: Opioids: risk of dependence and addiction Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing Insulins (all types): risk of cutaneous amyloidosis at injection site Letters and drug alerts sent to healthcare professionals in August 2020 24/09/2020
	Formulary Group decisions - August 2020 31/08/2020
	Drug Safety Update - August 2020 Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available over-the-counter: new measures to support safe use Clozapine and other antipsychotics: monitoring blood concentrations for toxicity Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors Isotretinoin (Roaccutane▼): reminder of important risks and precautions Emollients and risk of severe and fatal burns: new resources available Letters and drug alerts sent to healthcare professionals in July 2020 Medical Device Alerts issued in July 2020 27/08/2020
	NHS Grampian emollient choices has now been updated: NHS Grampian emollient choices - August 2020 NHS Grampian emollient choices - August 2020 [intranet link] For more information see - 13.2.1 Emollients 19/08/2020
	Drug Safety Update July 2020 Systemically administered VEGF pathway inhibitors: risk of aneurysm Liposomal and lipid-complex formulations: name change to reduce medication errors Letters and drug alerts sent to healthcare professionals in June 2020 Medical Device Alerts issued in June 2020 06/08/2020
	Formulary Group (Executive Group) decisions - July 2020 04/08/2020
	Formulary Group (Executive Group) decisions - June 2020 30/06/2020
	Drug Safety Update June 2020 Cyproterone acetate: new advice to minimise risk of meningioma Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, availability of reversal agents Letters and drug alerts sent to healthcare professionals in May 2020 29/06/2020
	Formulary Group (Executive Group) decisions - May 2020 02/06/2020
	Coronavirus (COVID-19) - Antibiotic Management/Antimicrobial Stewardship in the Context of the COVID-19 Pandemic, Version 2 27/05/2020
	Guidance for repurposing Prescription Only Medicines (PoMs) in Care Homes and Hospices during the COVID-19 pandemic: Covering letter for this guidance Training video from Healthcare Improvement Scotland Guidance for repurposing Prescription Only Medicines (PoMs) in Care Homes and Hospices Template for repurposing medicine assessment Template repurposing log for PoMs 26/05/2020
	Coronavirus (COVID-19) - Guidance For GP Practices And Care Homes Regarding The Supply And Administration Of Palliative Care Medicines During COVID-19, Version 1.1 26/05/2020
	Drug Safety Update May 2020 Coronavirus (COVID-19): new dedicated Yellow Card reporting site for medicines and medical devices Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) Letters and drug alerts sent to healthcare professionals in April 2020 25/05/2020
	MHRA: Patients informed to exchange Emerade 500 micrograms adrenaline pens for a different brand 19/05/2020
	Grampian Joint Formulary Status for SMC advice published April 2019 to March 2020 [updated to April 2020 decisions] 12/05/2020
	MHRA: Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) 11/05/2020
	Formulary Group (Executive Group) decisions - April 2020 05/05/2020
	Coronavirus (COVID-19) - Frequently Asked Questions – Guidance for GP Practices and Care Homes regarding the Supply and Administration of Palliative Care Medicines during COVID-19, Version 1 30/04/2020
	Drug Safety Update - April 2020 Coronavirus (COVID-19): latest guidance for medicines safety Letters and drug alerts sent to healthcare professionals in March 2020 28/04/2020
	Coronavirus (COVID-19) - Medication use for Acute behavioural disturbance during the COVID-19 Pandemic 21/04/2020
	Coronavirus (COVID-19) - PGD for the administration of medicines included in the COVID-19 End Of Life Care PGD Formulary 20/04/2020
	Coronavirus (COVID-19) - Liverpool Drug Interactions Group - Interactions with Experimental COVID-19 Therapies 16/04/2020
	Coronavirus (COVID-19) - Managing antipsychotic depots or long-acting injections during the COVID-19 Pandemic, Version 1 15/04/2020
	Coronavirus (COVID-19) - Monitoring lithium during the COVID-19 Pandemic 14/04/2020
	Coronavirus (COVID-19) - Maintaining clozapine treatment during the COVID-19 outbreak 09/04/2020
	Coronavirus (COVID-19) - Antibiotic management in frail older people with respiratory infections during the COVID-19 Pandemic, Version 1 08/04/2020
	Coronavirus (COVID-19) - Guidance for switching warfarin to DOACs for Adults with non-valvular AF and DVT/PE during the COVID-19 Pandemic 07/04/2020
	Formulary Group minute - 18 February 2020 07/04/2020
	Formulary Group (Executive Group) decisions - March 2020 01/04/2020
	New monitoring schedules for DMARDS available. The new schedules are independent of indication, and have been agreed with the specialties (rheumatology/ophthalmology/dermatology/paediatrics) in Secondary care. 25/03/2020
	Coronavirus (COVID-19) - PGD to allow to Community Pharmacists to pack down paracetamol PoM packs for self-isolating patients who have fever associated with COVID-19 is now available - Covering letter and Patient Group Direction 23/03/2020
	Drug Safety Update - March 2020 Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections Baricitinib (Olumiant▼): risk of venous thromboembolism SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression 18/03/2020
	EMA - Suspension of ulipristal acetate (5mg) for uterine fibroids during ongoing EMA review of liver injury risk - March 2020 18/03/2020
	Formulary Group minute - 21 January 2020 11/03/2020
	Formulary Group decisions - February 2020 03/03/2020
	Drug Safety Update - February 2020 Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions Valproate (Epilim▼, Depakote▼) pregnancy prevention programme: updated educational materials Nexplanon (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury and implant migration Support Yellow Card: report suspected reactions in patients taking multiple medicines 18/02/2020
	Updated guidance regarding the recommended Nexplanon insertion site 13/02/2020
	Formulary Group minute - 17 December 2019 11/02/2020
	Formulary Group minute - 19 November 2019 11/02/2020
	Formulary Group decisions - January 2020 04/02/2020
	Drug Safety Update - January 2020 28/01/2020
	Formulary Group decisions - December 2019 31/12/2019
	Drug Safety Update - December 2019 17/12/2019
	Formulary Group minute - 17 September 2019 04/12/2019
	Formulary Group decisions - November 2019 03/12/2019
	MHRA: Class 2 Medicines recall: Emerade 150, 300 and 500 microgram solution for injection in pre-filled syringe (MDR 57-08/19) - November 2019 02/12/2019
	Drug Safety Update - November 2019 25/11/2019
	Drug Safety Update: Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions - October 2019 23/10/2019
	October 2019 Formulary Group Meeting Cancelled 22/10/2019
	Drug Safety Update - October 2019 21/10/2019
	NHS Grampian HIV medicines list (October 2019) 15/10/2019
	Formulary Group minute - 20 August 2019 04/10/2019
	Formulary Group decisions - September 2019 01/10/2019
	Drug Safety Update - September 2019 19/09/2019
	Formulary Group minute - 16 July 2019 03/09/2019
	Formulary Group decisions - August 2019 03/09/2019
	Q&A: Can miconazole oral gel be used by patients taking a statin? 02/09/2019
	Drug Safety Update: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping - 30 August 2019 02/09/2019
	Drug Safety Update - August 2019 20/08/2019
	Formulary Group decisions - July 2019 30/07/2019
	Formulary Group minute - 18 June 2019 23/07/2019
	Q&A - Excipients: What are the general considerations for vegan patients? 22/07/2019
	Drug Safety Update - July 2019 22/07/2019
	Formulary Group minute - 21 May 2019 03/07/2019
	Formulary Group decisions - June 2019 02/07/2019
	Drug Safety Update - June 2019 21/06/2019
	Grampian Joint Formulary Status for SMC advice published April 2018 to March 2019 (updated May 2019) 05/06/2019
	Formulary Group minute - 16 April 2019 04/06/2019
	Formulary Group decisions - May 2019 04/06/2019
	SDcep Drug Prescribing for Dentistry 04/06/2019
	SAPG New guidance on antibiotic dosing in obesity 04/06/2019
	Formulary Group minute - 19 March 2019 01/05/2019
	Formulary Group decisions - April 2019 01/05/2019
	Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme 24/04/2019
	Drug Safety Update - April 2019 17/04/2019
	Formulary Group minute - 19 February 2019 08/04/2019
	Formulary Group decisions - March 2019 03/04/2019
	Drug Safety Update - March 2019 26/03/2019
	Formulary Group decisions - February 2019 05/03/2019
	Formulary Group minute - 15 January 2019 26/02/2019
	Gabapentin and pregabalin will become Schedule 3 Controlled Drugs in April 2019 / FAQ document 21/02/2019
	Drug Safety Update - February 2019 18/02/2019
	Formulary Group decisions - January 2019 25/01/2019
	Formulary Group minute - 18 December 2018 23/01/2019
	Drug Safety Update - January 2019 10/01/2019
	HIV medicines list updated 09/01/2019
	Formulary Group minute - 20 November 2018 06/01/2019
	Drug Safety Update - December 2018 04/01/2019
	Formulary Group decisions - December 2018 31/12/2018
	Drug Safety Update - November 2018 14/12/2018
	Teething gels for babies and children to be sold in pharmacies only 14/12/2018
	Formulary Group decisions - November 2018 14/12/2018
	Formulary Group minute - 16 October 2018 14/12/2018
	Formulary Group decisions - October 2018 31/10/2018
	Drug Safety Update - October 2018 31/10/2018
	Formulary Group minute - 18 September 2018 31/10/2018
	Shortage of Epipen 01/10/2018
	Formulary Group decisions - September 2018 01/10/2018
	Drug Safety Update - September 2018 01/10/2018
	Formulary Group minute - 21 August 2018 01/10/2018
	Formulary Group decisions - August 2018 03/09/2018
	Drug Safety Update - August 2018 28/08/2018
	Formulary Group minute - 17 July 2018 28/08/2018
	Formulary Group decisions - July 2018 28/08/2018
	Drug Safety Update - July 2018 28/08/2018
	Formulary Group minute - 19 June 2018 23/07/2018
	Formulary Group decisions - June 2018 23/07/2018
	Drug Safety Update - June 2018 23/07/2018
	Q&A - Which oral antihistamines are safe to use whilst breastfeeding? 23/07/2018
	Q&A - Is there a lactose-free antidepressant? 23/07/2018
	Q&A - Glucosamine – what are the adverse effects? 23/07/2018
	Impact newsletter - May 2018 23/07/2018
	Formulary Group minute - 15 May 2018 23/07/2018
	Formulary Group decisions - May 2018 23/07/2018
	Drug Safety Update - May 2018 23/07/2018
	SIGN 151 - Management of stable angina 23/07/2018
	Q&A - Which medicines require extra care when switching between liquid and tablet/capsule formulations? 23/07/2018
	Q&A - Gabapentin and pregabalin—are they safe whilst breastfeeding? 23/07/2018
	Formulary Group minute - 17 April 2018 23/07/2018
	Formulary Group decisions - April 2018 23/07/2018
	Drug Safety Update - April 2018 23/07/2018
	Q&A - Which medicines can be used to treat intermittent allergic rhinitis during pregnancy? 23/07/2018
	Q&A - Do statins cause alopecia? 23/07/2018
	Formulary Group minute - 20 March 2018 23/07/2018
	Formulary Group decisions - March 2018 23/07/2018
	Drug Safety Update - March 2018 23/07/2018
	SIGN 155 - Pharmacological management of migraine 23/07/2018
	Q&A - Oseltamivir or zanamivir – can mothers breastfeed after treatment for influenza? 23/07/2018
	Q&A - Is there a lactose-free hormone replacement therapy (HRT)? 23/07/2018
	Formulary Group minute - 20 February 2018 23/07/2018
	Formulary Group decisions - February 2018 23/07/2018
	Drug Safety Update - February 2018 23/07/2018
	Impact newsletter - January 2018 23/07/2018
	Formulary Group minute - 16 January 2018 23/07/2018
	Formulary Group decisions - January 2018 23/07/2018
	Drug Safety Update - January 2018 23/07/2018
	Formulary Group minute - 19 December 2017 23/07/2018
	Formulary Group decisions - December 2017 23/07/2018
	Drug Safety Update - December 2017 23/07/2018
	SIGN 154 and 116 - Management of diabetes 23/07/2018
	Q&A - What are the clinically significant drug interactions with cigarette smoking? 23/07/2018
	Q&A - Can high dose loperamide be used to reduce stoma output? 23/07/2018
	Impact newsletter - November 2017 23/07/2018
	Formulary Group minute - 21 November 2017 23/07/2018
	Formulary Group decisions - November 2017 23/07/2018
	Drug Safety Update - November 2017 23/07/2018
	Q&A - Is there an interaction between warfarin and proton pump inhibitors? 23/07/2018
	Formulary Group minute - 17 October 2017 23/07/2018
	Formulary Group decisions - October 2017 23/07/2018
	Drug Safety Update - October 2017 23/07/2018
	Formulary Group minute - 19 September 2017 23/07/2018
	Formulary Group decisions - September 2017 23/07/2018
	Drug Safety Update - September 2017 23/07/2018
	Impact newsletter - August 2017 23/07/2018
	Formulary Group minute - 15 August 2017 23/07/2018
	Formulary Group decisions - August 2017 23/07/2018
	Drug Safety Update - August 2017 23/07/2018
	SIGN 150 - Cardiac rehabilitation 23/07/2018
	SIGN 149 - Risk estimation and the prevention of cardiovascular disease 23/07/2018
	Impact newsletter - July 2017 23/07/2018
	Formulary Group minute - 18 July 2017 23/07/2018
	Formulary Group decisions - July 2017 23/07/2018
	Drug Safety Update - July 2017 23/07/2018
	Formulary Group minute - 20 June 2017 23/07/2018
	Formulary Group decisions - June 2017 23/07/2018
	Drug Safety Update - June 2017 23/07/2018
	Q&A - Is there an interaction between bisphosphonates and proton pump inhibitors? 23/07/2018
	Q&A - Do proton pump inhibitors reduce the clinical efficacy of clopidogrel? 23/07/2018
	Impact newsletter - May 2017 23/07/2018
	Drug Safety Update - May 2017 23/07/2018
	Formulary Group minute - 18 April 2017 23/07/2018
	Formulary Group decisions - April 2017 23/07/2018
	Drug Safety Update - April 2017 23/07/2018
	Formulary Group minute - 21 March 2017 23/07/2018
	Formulary Group decisions - March 2017 23/07/2018
	Drug Safety Update - March 2017 23/07/2018
	Q&A - What are the differences between different brands of mesalazine tablets? 23/07/2018
	Q&A - Is there an interaction between erythromycin and statins? 23/07/2018
	Formulary Group minute - 21 February 2017 23/07/2018
	Formulary Group decisions - February 2017 23/07/2018
	Drug Safety Update - February 2017 23/07/2018
	Q&A - What is the optimal prokinetic dose of erythromycin in adults? 23/07/2018
	SIGN 146 - Cutaneous melanoma 23/07/2018
	Formulary Group decisions - January 2017 23/07/2018
	Formulary Group minute - 17 January 2017 23/07/2018
	Drug Safety Update - January 2017 23/07/2018